Epinomics Status
The company was acquired by 10x Genomics for an undisclosed amount on March 5, 2018.
Developer of a DNA sequencing technology designed to revolutionize personalized medicine. The company's DNA sequencing technology leverages big data analytics and proprietary epigenomics technology with improvement over existing technologies to impact drug development and clinical applications, enabling researchers to decode the programming of human genome.
Year Founded
2013
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Acquired/Merged (Operating Subsidiary)
-
Financing Status
Formerly VC-backed
Epinomics News and Updates
Peptide-mediated delivery of CRISPR enzymes for the efficient ...
Nature.com | April 25, 2023
エピジェネティクス（epigenetics）とは：日経バイオテクONLINE
日経BP | November 10, 2022
Pooled screening of CAR T cells identifies diverse immune signaling ...
Science | November 9, 2022
RASA2 ablation in T cells boosts antigen sensitivity and long-term ...
Nature.com | August 24, 2022
Economic recovery requires first protecting the vulnerable
Quartz | July 15, 2020
单细胞测序公司10x Genomics上市：市值超50亿美元未受诉讼影响_ ...
Sohu | September 14, 2019
Epinomics's Verticals
Epinomics Primary Industry Sector / Group / Code
Epinomics's Trends
Headquarters
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ CountryUnited States
Epinomics's Keywords
mood_badFeed is empty.
Add a review